You have free access to this content

Cancer

Cover image for Vol. 118 Issue 20

15 October 2012

Volume 118, Issue 20

Pages 4911–5183

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Communications
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Communications

    1. Top of page
    2. CancerScope
    3. Communications
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      A note from history: Landmarks in history of cancer, part 4 (pages 4914–4928)

      Steven I. Hajdu

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27509

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Major events and discoveries that took place between 1860 and 1910 are reviewed.

  3. Original Articles

    1. Top of page
    2. CancerScope
    3. Communications
    4. Original Articles
    5. Correspondence
    1. Disease Site

      Breast Disease
      You have free access to this content
      Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases (pages 4929–4935)

      Laurien D. C. Hoefnagel, Cathy B. Moelans, S. L. Meijer, Henk-Jan van Slooten, Pieter Wesseling, Jelle Wesseling, Pieter J. Westenend, Joost Bart, Cornelis A. Seldenrijk, Iris D. Nagtegaal, Joost Oudejans, Paul van der Valk, Carla H. van Gils, Elsken van der Wall and Paul J. van Diest

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27518

      • original image
      • original image
      • original image
      • original image

      Estrogen receptor α and progesterone receptor conversion from positive in primary breast cancer to negative in distant metastases has negative prognostic value.

    2. You have free access to this content
      Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancer (pages 4936–4943)

      Michelle M. Kim, Shaheenah Dawood, Pamela Allen, Aysegul A. Sahin, Wendy A. Woodward, Benjamin D. Smith, Eric A. Strom, Kelly K. Hunt, Funda Meric-Bernstam, Ana Maria Gonzalez-Angulo and Thomas A. Buchholz

      Version of Record online: 17 APR 2012 | DOI: 10.1002/cncr.27502

      • original image
      • original image

      This is the first study to examine the predictive efficacy of trastuzumab on locoregional outcomes in relation to hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Patients with HR+/HER2+ disease who received trastuzumab had equally excellent locoregional control as those with HR+/HER2− tumors, whereas a similar benefit could not be demonstrated among patients with HR−/HER2+ disease.

    3. You have free access to this content
      Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy (pages 4944–4952)

      Alice Y. Ho, Gaorav Gupta, Tari A. King, Carmen A. Perez, Sujata M. Patil, Katherine H. Rogers, Yong Hannah Wen, Edi Brogi, Monica Morrow, Clifford A. Hudis, Tiffany Traina, Beryl McCormick, Simon N. Powell and Mark E. Robson

      Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27480

      • original image
      • original image
      • original image

      Favorable 5-year locoregional and distant control rates are achievable in patients with T1bN0 triple-negative breast cancers, approximately 66% of whom receive chemotherapy. When they receive multimodality therapy, these patients are excellent candidates for breast-conserving therapy.

    4. Gastrointestinal Disease
      You have free access to this content
      Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence (pages 4953–4960)

      Ji Hyung Nam, Il Ju Choi, Soo-Jeong Cho, Chan Gyoo Kim, Jae Kwan Jun, Kui Son Choi, Byung-Ho Nam, Jun Ho Lee, Keun Won Ryu and Young-Woo Kim

      Version of Record online: 16 JUL 2012 | DOI: 10.1002/cncr.27495

      • original image
      • original image

      Compared to those for individuals who have never been screened in a region of high prevalence of gastric cancer, the odds ratio of having a higher stage of cancer decreased gradually from 0.53 in the group of individuals with >5-year intervals to 0.31 in the group with 1-year intervals. Endoscopy intervals of 3 years or less showed similar benefits, but family members of patients with gastric cancer may benefit from intervals of <3 years.

    5. You have free access to this content
      Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy? (pages 4961–4968)

      Sang Hui Moon, Dae Yong Kim, Ji Won Park, Jae Hwan Oh, Hee Jin Chang, Sun Young Kim, Tae Hyun Kim, Hee Chul Park, Doo Ho Choi, Ho-Kyung Chun, Jong Hoon Kim, Jin-hong Park and Chang Sik Yu

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27507

      • original image
      • original image

      ypStage in rectal cancer, defined according to the 7th edition of the American Joint Committee on Cancer staging system, predicts survival for most ypNT classifications. However, patients with ypStage I rectal cancer have a similar prognosis to those with ypStage 0 cancer, and risk grouping reflects more precise survival outcomes than ypStage.

    6. You have free access to this content
      Helicobacter pylori induces promoter methylation of E-cadherin via interleukin-1β activation of nitric oxide production in gastric cancer cells (pages 4969–4980)

      Fung-Yu Huang, Annie On-On Chan, Asif Rashid, Danny Ka-Ho Wong, Chi-Hin Cho and Man-Fung Yuen

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27519

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Helicobacter pylori induces E-cadherin methylation via interleukin-1β activation of nitric oxide (NO) production. This study reveals that NO may play a crucial role in epigenetic modification that links inflammation to carcinogenesis.

    7. You have free access to this content
      Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection (pages 4981–4990)

      Gabriel G. Malouf, Laurence Brugières, Marie-Cécile Le Deley, Sandrine Faivre, Monique Fabre, Valérie Paradis, Isabelle Aerts, Christophe Le Tourneau, Chantal Dreyer, Sophie Branchereau, Jacques Belghiti and Eric Raymond

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27520

      • original image
      • original image
      • original image
      • original image

      In the current study, a central pathological review was undertaken in all patients with the primary diagnosis of fibrolamellar hepatocellular carcinoma (FL-HCC) who underwent complete surgical resection at 3 reference surgical centers. The authors report that pure FL-HCC demonstrated epigenetic patterns and clinical characteristics at diagnosis and follow-up that differ from mixed FL-HCC. In this study, mixed FL-HCC was found to more closely resemble classic HCC both in terms of epigenetic features, clinical presentation, and outcome.

    8. Genitourinary Disease
      You have free access to this content
      Leapfrog volume thresholds and perioperative complications after radical prostatectomy (pages 4991–4998)

      Quoc-Dien Trinh, Maxine Sun, Jesse Sammon, Zhe Tian, Marco Bianchi, Shahrokh F. Shariat, Wooju Jeong, Khurshid R. Ghani, Claudio Jeldres, Paul Perrotte, Piyush K. Agarwal, Craig G. Rogers, James O. Peabody, Mani Menon and Pierre I. Karakiewicz

      Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27486

      Leapfrog volume thresholds can provide a highly accurate prediction of the probability of 2 important, detrimental, short-term outcomes after radical prostatectomy, even after accounting for hospital volume. The benefit of radical prostatectomy at institutions that meet Leapfrog volume thresholds may exceed the benefit of radical prostatectomy at other institutions when short-term outcomes are considered.

    9. You have free access to this content
      Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting : Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database (pages 4999–5007)

      David I. Chu, Daniel M. Moreira, Leah Gerber, Joseph C. Presti Jr, William J. Aronson, Martha K. Terris, Christopher J. Kane, Christopher L. Amling and Stephen J. Freedland

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27456

      In equal-access hospital settings, lower patient socioeconomic status was significantly associated with higher positive surgical margin risk after radical prostatectomy. Race, however, appears to be a more significant risk factor than socioeconomic status for biochemical recurrence, with low socioeconomic status black patients potentially being the most at risk.

    10. Head and Neck Disease
      You have free access to this content
      A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer (pages 5008–5014)

      Matthew G. Fury, Nancy Y. Lee, Eric Sherman, Donna Lisa, Katherine Kelly, Brynna Lipson, Diane Carlson, Hilda Stambuk, Sofia Haque, Ronglai Shen, Dennis Kraus, Jatin Shah and David G. Pfister

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27498

      • original image
      • original image
      • original image

      For patients with stage III/IVB head and neck squamous cell cancer (HNSCC), the addition of bevacizumab to high-dose cisplatin plus intensity-modulated radiation therapy does not increase toxicity to unacceptable levels. Efficacy results are encouraging and further study of bevacizumab in HNSCC is warranted.

    11. Lung Disease
      You have free access to this content
      p38 mitogen-activated protein kinase signaling, ERCC1 expression, and viability of lung cancer cells from never or light smoker patients (pages 5015–5025)

      David Planchard, Valérie Camara-Clayette, Nicolas Dorvault, Jean-Charles Soria and Pierre Fouret

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27510

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Lung cancer cells from never or light smokers rely on p38 mitogen-activated protein kinase signaling for their survival. p38β (MAPK11) isoforms are involved in that pathway and might contribute to ERCC1 expression and sensitization to cisplatin.

    12. Neuro-Oncology
      You have free access to this content
      Congruence of primary brain tumor patient and caregiver symptom report (pages 5026–5037)

      Terri S. Armstrong, Jeffrey S. Wefel, Ibrahima Gning, Alvina Acquaye, Elizabeth Vera-Bolanos, Mark R. Gilbert, Charles S. Cleeland and Tito Mendoza

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27483

      • original image
      • original image

      Caregivers of primary brain tumor patients have similar assessments of symptom severity (highly congruent) with patient self-report, regardless of neurocognitive function or Karnofsky performance status. These findings suggest that caregivers may serve as proxy report of symptoms for primary brain tumor patients

    13. You have free access to this content
      Trabectedin has promising antineoplastic activity in high-grade meningioma (pages 5038–5049)

      Matthias Preusser, Sabine Spiegl-Kreinecker, Daniela Lötsch, Adelheid Wöhrer, Maria Schmook, Karin Dieckmann, Walter Saringer, Christine Marosi and Walter Berger

      Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.27460

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Aggressive meningiomas are rare but are a therapeutic challenge. The current data indicate that the novel antineoplastic agent trabectedin, which is used for sarcomas and ovarian cancer, may be a promising new therapeutic option for aggressive meningiomas.

    14. Soft Tissue and Bone Sarcoma
      You have free access to this content
      Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients : The Italian Sarcoma Group Experience (1983-2006) (pages 5050–5059)

      Alessandra Longhi, Stefano Ferrari, Angela Tamburini, Roberto Luksch, Franca Fagioli, Gaetano Bacci and Cristina Ferrari

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27493

      • original image
      • original image
      • original image

      In very long-term survivors of bone sarcoma (30 years after diagnosis), an increase in second primary cancer is observed as time passes, whereas the probability of developing recurrent sarcoma decreases. This study confirms the greater incidence of second malignant neoplasms and of cardiotoxicity in women.

    15. Discipline

      Bioethics and Legal Oncology
      You have free access to this content
      Ethical aspects of participation in the Database of Genotypes and Phenotypes of the National Center for Biotechnology Information : The Cancer and Leukemia Group B Experience (pages 5060–5068)

      Jeffrey Peppercorn, Iuliana Shapira, Teressa Deshields, Deanna Kroetz, Paula Friedman, Patricia Spears, Deborah E. Collyar, Lawrence N. Shulman, Lynn Dressler and Monica M. Bertagnolli

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27515

      The rapid pace of genetics research, coupled with evolving standards for informed consent, can create ethical challenges regarding future use of tissue or information from completed clinical trials. Although modern standards for informed consent should not prohibit research or sharing of data consistent with participants' intent and the public interest, there is an urgent need for national consensus on the appropriate use of archived tissue and standardized informed consent for future research among cancer clinical trial participants.

    16. Clinical Trials
      You have free access to this content
      Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases (pages 5069–5077)

      Amit K. Garg, Almon S. Shiu, James Yang, Xin-Shelley Wang, Pamela Allen, Barry W. Brown, Patricia Grossman, Erik K. Frija, Mary Frances McAleer, Syed Azeem, Paul D. Brown, Laurence D. Rhines and Eric L. Chang

      Version of Record online: 17 APR 2012 | DOI: 10.1002/cncr.27530

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Single-session stereotactic body radiotherapy is both safe and effective in the treatment of selected patients with spinal metastases. Patients and clinicians may expect durable local control and limited toxicity, even for tumors that are near the spinal canal.

    17. Dermatopathology
      You have free access to this content
      Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors (pages 5078–5083)

      Yevgeniy Balagula, Alyx Rosen, Belinda H. Tan, Klaus J. Busam, Melissa P. Pulitzer, Robert J. Motzer, Darren R. Feldman, Jason A. Konner, Diane Reidy-Lagunes, Patricia L. Myskowski and Mario E. Lacouture

      Version of Record online: 21 MAR 2012 | DOI: 10.1002/cncr.27505

      • original image
      • original image
      • original image

      Anticancer therapies, including conventional cytotoxic and novel targeted agents, are associated with a wide spectrum of dermatologic adverse events, but there are insufficient data on their clinical and histopathologic characteristics. The authors describe clinical and histopathologic attributes of mammalian target of rapamycin inhibitor-associated rashes to improve our understanding of the underlying pathophysiology of this particular adverse event and to facilitate the development of effective, mechanism-based interventions to mitigate this significant toxicity.

    18. Disparities Research
      You have free access to this content
      Insurance and inpatient care : Differences in length of stay and costs between surgically treated cancer patients (pages 5084–5091)

      Cathy J. Bradley, Bassam Dahman and Harry D. Bear

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27508

      Health insurance affects the need for health care and the amount of health care received. Uninsured and Medicaid-insured patients with lung and colon cancer who undergo resection have longer lengths of stay and higher inpatient costs than privately insured patients; however, patients with breast cancer who do not have private insurance have shorter lengths of stay when they do not undergo breast reconstruction.

    19. You have free access to this content
      Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008 (pages 5092–5099)

      Priti Bandi, Vilma Cokkinides, Robert A. Smith and Ahmedin Jemal

      Version of Record online: 20 MAR 2012 | DOI: 10.1002/cncr.27529

      The findings of this study demonstrate that generally reported national declines in colorectal cancer screening with home-based fecal occult blood test (FOBT) in the past decade were restricted to higher socioeconomic subgroups and did not extend to lower socioeconomic subgroups. These trends suggest the continued availability and acceptance of FOBT in socially and economically disadvantaged groups.

    20. You have free access to this content
      Receipt of recommended radiation therapy among rural and urban cancer patients (pages 5100–5109)

      Laura-Mae Baldwin, Shilpen Patel, C. Holly A. Andrilla, Roger A. Rosenblatt and Mark P. Doescher

      Version of Record online: 26 JUN 2012 | DOI: 10.1002/cncr.27488

      • original image
      • original image
      • original image

      Rural cancer patients are less likely than their urban counterparts to receive radiation therapy for breast cancer, but are equally likely to receive radiation therapy for other cancer types. Sociodemographic characteristics, cancer types and stages, and state of residence appear to have a greater influence over whether a patient receives radiation therapy than rural residence.

    21. You have free access to this content
      Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007 (pages 5110–5116)

      Edgar P. Simard, Stacey Fedewa, Jiemen Ma, Rebecca Siegel and Ahmedin Jemal

      Version of Record online: 15 JUN 2012 | DOI: 10.1002/cncr.27606

      • original image

      The authors report widening disparities in cervical cancer death rates during the period from 1993 to 2007 by individual levels of educational attainment (as a proxy for socioeconomic status) among non-Hispanic white women and non-Hispanic black women. In 2007, approximately 74% of all cervical cancer deaths may have been averted if there had been no disparities in socioeconomic status.

    22. You have free access to this content
      Neighborhood-level socioeconomic determinants impact outcomes in nonsmall cell lung cancer patients in the Southeastern United States (pages 5117–5123)

      Loretta Erhunmwunsee, Mary-Beth M. Joshi, Debbi H. Conlon and David H. Harpole Jr.

      Version of Record online: 5 MAR 2012 | DOI: 10.1002/cncr.26185

      • original image
      • original image
      • original image

      Low socioeconomic status was an independent prognostic factor for poor survival in patients with both early and advanced stage nonsmall cell lung cancer. Patients who lived in areas with high poverty levels, low median income, and low education levels had worse mortality.

    23. Epidemiology
      You have free access to this content
      Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative (pages 5124–5131)

      Deepa Jagtap, Carol A. Rosenberg, Lisa W. Martin, Mary Pettinger, Janardan Khandekar, Dorothy Lane, Ira Ockene and Michael S. Simon

      Version of Record online: 20 MAR 2012 | DOI: 10.1002/cncr.27497

      The authors analyze data from the Women's Health Initiative (WHI) to assess whether statins are associated with a decreased risk of melanoma. The results indicate that there is no significant association between statin use and melanoma risk among postmenopausal women in the WHI.

    24. Outcomes Research
      You have free access to this content
      Costs and trends in pancreatic cancer treatment (pages 5132–5139)

      Caitriona B. O'Neill, Coral L. Atoria, Eileen M. O'Reilly, Jennifer LaFemina, Martin C. Henman and Elena B. Elkin

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27490

      • original image
      • original image
      • original image
      • original image

      Despite poor prognosis and short survival, the economic burden of pancreatic cancer in the elderly is substantial. Demographic trends, greater use of targeted therapies, and possible implementation of screening strategies are likely to impact treatment patterns and costs in the future.

    25. Pediatric Oncology
      You have free access to this content
      Slow down to stay alive : HER4 protects against cellular stress and confers chemoresistance in neuroblastoma (pages 5140–5154)

      Yingqi Hua, Kirill Gorshkov, Yanwen Yang, Wenyi Wang, Nianxiang Zhang and Dennis P. M. Hughes

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27496

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      In this study, the authors demonstrate an elevated expression of human epidermal growth factor receptor 4 in response to cellular stress, which may regulate the cell cycle, revealing its role in protecting cancer cells from death.

    26. Psychosocial Oncology
      You have free access to this content
      Positive and negative psychosocial impact of being diagnosed with cancer as an adolescent or young adult (pages 5155–5162)

      Keith M. Bellizzi, Ashley Smith, Steven Schmidt, Theresa H. M. Keegan, Brad Zebrack, Charles F. Lynch, Dennis Deapen, Margarett Shnorhavorian, Bradley J. Tompkins, Michael Simon and and the Adolescent and Young Adult Health Outcomes and Patient Experience (AYA HOPE) Study Collaborative Group

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27512

      Findings draw attention to specific psychosocial areas that may necessitate needed support and services to help adolescents and young adults with cancer minimize the negative consequences of cancer while promoting or supporting positive aspects during an already profound time of developmental change and turmoil.

    27. Quality of Life
      You have free access to this content
      Cost effectiveness of gene expression profiling for early stage breast cancer : A decision-analytic model (pages 5163–5170)

      Mo Yang, Suja Rajan and Amalia M. Issa

      Version of Record online: 22 FEB 2012 | DOI: 10.1002/cncr.27443

      • original image
      • original image

      The authors evaluated the cost effectiveness of recurrence score-guided treatment using 2 commercially available gene expression profiling (GEP) tests from a third-party payer's perspective. A Markov model suggests that MammaPrint is a more cost-effective GEP test compared with Oncotype DX at a threshold willingness-to-pay of $50,000 per quality-adjusted life-year.

    28. Symptom Control and Palliative Care
      You have free access to this content
      Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy : North Central Cancer Treatment Group trial N08C1 (pages 5171–5178)

      Brandi N. Reeves, Shaker R. Dakhil, Jeff A. Sloan, Sherry L. Wolf, Kelli N. Burger, Arif Kamal, Nguyet A. Le-Lindqwister, Gamini S. Soori, Anthony J. Jaslowski, Joseph Kelaghan, Paul J. Novotny, Daniel H. Lachance and Charles L. Loprinzi

      Version of Record online: 13 MAR 2012 | DOI: 10.1002/cncr.27489

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Patients with worse paclitaxel-associated acute pain syndrome severities appear to have more eventual chemotherapy-induced peripheral neuropathy. This provides support for the concept that the paclitaxel-associated acute pain syndrome is a form of nerve pathology.

  4. Correspondence

    1. Top of page
    2. CancerScope
    3. Communications
    4. Original Articles
    5. Correspondence
    1. You have free access to this content
      The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia (page 5179)

      Ester M. Orlandi, Paolo Bernasconi and Cristiana Pascutto

      Version of Record online: 17 APR 2012 | DOI: 10.1002/cncr.27525

    2. You have free access to this content
    3. You have free access to this content
      Nilotinib versus imatinib: Molecular mechanism(s) of its better efficacy (pages 5181–5182)

      Rumiana Bakalova, Zhivko Zhelev and Lubomir Spasov

      Version of Record online: 25 APR 2012 | DOI: 10.1002/cncr.27479

      • original image
    4. You have free access to this content

SEARCH

SEARCH BY CITATION